Catalyst Pharmaceuticals initiated with an Outperform at Baird

Baird analyst Joel Beatty last night initiated coverage of Catalyst Pharmaceuticals (CPRX) with an Outperform rating and $28 price target Catalyst is a biopharmaceutical company that commercializes three drugs for rare neuro diseases, the analyst tells investors in a research note. The firm believes the commercialization of both Firdapse for Lambert-Eaton myasthenic syndrome and Agamree for Duchenne muscular dystrophy will continue to go well. That said, it is cautious on Fycompa given that generic competition for this agent is expected to enter the market in May.